肥胖治療藥物之最新進展：Phentermine/Topiramate複方

Advances in the Treatment of Obesity: The Combination of Phentermine and Topiramate

邵時傑(Shih-Chieh Shao)；葉鳳英(Liu Pheng-Ying Yeh)

肥胖 ； 藥物 ； Phentermine ； Topiramate ； Obesity ； Medication

醫學與健康期刊

4卷1期（2015 / 03 / 01）

13 - 21

繁體中文

肥胖是許多慢性病重要危險因子，也是全球重視的健康議題。過去許多藥物曾被用於肥胖治療，但卻因安全性考量先後下市，目前僅少數藥物被核准於肥胖長期治療。2012年7月，美國食品藥物管理局核准phentennine/topiramate複方上市，用於肥胖或體重過重且至少有一項肥胖相關共病症（包含第二型糖尿病、高血壓或高血脂症等）病人，搭配飲食與運動控制的長期藥物治療。本文將簡介該藥的藥理特性與相關臨床試驗結果，以供醫療人員參考。

Obesity is a major risk factor for numerous chronic diseases and a global health-related issue. Many drugs used for weight loss have been withdrawn from the market for safety reasons, and only a few medications are currently approved for the long-term treatment of obesity. In July 2012, U.S. Food and Drug Administration approved the combination of phentermine and topiramate as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (body mass index, BMI of ≥30kg/m^2) or overweight adults (BMI≥27kg/m^2) having at least one obesity-related comorbidity (e.g., type 2 diabetes mellitus, hypertension, or hyperlipidemia). This article provides health professionals with concise information about the pharmacological action underlying their combined use and the results of clinical trials.

1. Orlistat: label information. (Cited on July 1, 2014. Available form http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020766s029lbl.pdf).
2. Lorcaserin: label information. (Cited on July 1, 2014. Available form http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf).
3. 衛生福利部國民健康署肥胖防治網：臺灣過重及肥胖的盛行率。引用：http://obesity.hpa.gov.tw/web/content.aspx?T=C&no=243。引用時間：10；31/2013
4. Qsymia: Label information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf. Accessed July 1, 2014.
5. Allison, DB,Gadde, KM,Garvey, WT(2012).Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).Obesity,20,330-42.
6. Cameron, F,W, G,McKeage, K(2012).Phentermine and topiramate extended release (Qsymia™): first global approval.Drugs,72,2033-42.
7. Colman, E,Golden, J,Roberts, M,Egan, A,Weaver, J,Rosebraugh, C(2012).The FDA's assessment of two drugs for chronic weight management.N Engl J Med,367,1577-9.
8. Finkelstein, EA,Kruger, E,Karnawat, S(2014).Cost-Effectiveness Analysis of Qsymia for Weight Loss.Pharmacoeconomics,2014
9. Food and Drug Administration. Clinical Briefing Document, Endocrine and Metabolic Drugs Advisory Committee Meeting, February 22, 2012. New Drug Application 22580: VI-052 Qnexa (phentermine/topiramate). Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM292315.pdf.Accessed July 1, 2014.
10. Gadde, KM,A, D,Ryan, DH,Peterson, CA,Troupin, B,Schwiers, ML,Day, WW(2011).Effects of low-dose, controlledrelease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.Lancet,377,1341-52.
11. Garvey, WT(2013).Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complication-scentric approach to obesity medical management.Expert Opin Drug Saf,12,741-56.
12. Garvey, WT,Ryan, DH,Henry, R(2014).Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.Diabetes Care,37,912-21.
13. Garvey, WT,Ryan, DH,Look, M(2012).Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.Am J Clin Nutr,95,297-308.
14. Jensen, MD,Ryan, DH,Apovian, CM(2014).2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.J Am Coll Cardiol,63,2985-3023.
15. Jordan, J,Astrup, A,Engeli, S(2014).Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.J Hypertens,32,1178-88.
16. Kim, GW,Lin, JE,Blomain, ES(2014).Antiobesity pharmacotherapy: new drugs and emerging targets.Clin Pharmacol Ther,95,53-66.
17. Kiortsis, DN(2013).A review of the metabolic effects of controlledrelease Phentermine/Topiramate.Hormones,12,507-16.
18. Margulis, AV,Mitchell, AA,Gilboa, SM(2012).Use of topiramate in pregnancy and risk or oral clefts.Am J Obstet Gynecol,207,405.e1-7.
19. Shin, JH,Gadde, KM(2013).Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity.Diabetes Metab Syndr Obes,6,131-39.
20. Smith, SM,Meyer, M,Trinkley, KE(2013).Phentermine/topiramate for the treatment of obesity.Ann Pharmacother,47,340-9.
21. Supuran, CT(2012).Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.Expert Opin Emerg Drugs,17,11-5.
22. WHO Expert Consultation(2004).Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.Lancet,363,157-63.
23. Yanovski, SZ,Yanovski, JA(2014).Long-term drug treatment for obesity: a systematic and clinical review.JAMA,311,74-86.
24. 彭仁奎、黃國晉、陳慶餘(2006)。肥胖與代謝症候群。基層醫學，21，367-71。